Edwards Lifesciences Corp 4

Edwards Lifesciences CEO Bernard J. Zovighian transferred existing holdings between accounts and sold about 2,921 shares of common stock held via a trust for roughly $245,000.

On July 27, 2026, Edwards Lifesciences Corp. CEO Bernard J. Zovighian reported intra-account transfers and a small sale involving the company’s common stock. Two non-price “G” code transactions reflect movements of 98,845 shares held directly and 11,836.201 shares held indirectly via a trust at a reference price of $319.6499, indicating reclassification or internal transfers rather than open-market trades. In addition, a trust-related sale (“S”) of 2,920.5511 common shares at $83.9342 per share generated proceeds of roughly $245,000, leaving the trust with 8,915.6499 shares and a separate 401(k) account with 3,733.5603 shares. Overall, Zovighian continues to hold a meaningful stake through direct, trust, and 401(k) ownership, and the Form 4 notes that it does not encompass all securities beneficially owned by him.

Filing Facts

CIK

1099800

Ticker

EW

Form

4

Source Type

sec

Accession

0001225208-26-006743

Alert Tier

6